Latest Breaking News On - Codexis inc - Page 5 : comparemela.com

Codexis, Inc (NASDAQ:CDXS) Receives $6 80 Consensus Target Price from Analysts

Codexis, Inc. (NASDAQ:CDXS – Get Free Report) has earned an average rating of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among […]

Codexis incCodexis company profileAmeriprise financial incOpaleye management incMillennium managementGet free reportGet freePerformance enzymesCodexis dailyNasdaq cdxs

Codexis, Inc (NASDAQ:CDXS) Receives $6 80 Consensus Target Price from Analysts

Codexis, Inc. (NASDAQ:CDXS – Get Free Report) has received an average rating of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among […]

Codexis incVanguard group incOpaleye management incNantahala capital managementBlackrock incGet free reportCapital managementOpaleye managementGet freePerformance enzymesCodexis dailyNasdaq cdxs

Head to Head Review: Takeda Pharmaceutical (NYSE:TAK) vs Nurix Therapeutics (NASDAQ:NRIX)

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Volatility and Risk Takeda Pharmaceutical has a beta […]

United statesSan franciscoXenetic biosciencesLeuplin enantoneSosei heptaresSelecta biosciencesHeidelberg pharmaFalk pharma gmbTakecab vocintiAdynovate adynoviSelecta bioscienceFalk pharmaHemofil immunate immunineGattex revestivePantoloc controlocGenevant sciences corporation

Codexis, Inc (NASDAQ:CDXS) Q4 2023 Earnings Call Transcript

Codexis, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.16.

Dan ariasKayla hostetlerCarrie mckimStefan lutzJohn maraganoreKevin norrettMasad damhaEvan stamplerJim lalondeBrandon couillardSynthesis innovation labCodexis incExchange commissionNestle health scienceAlnylam pharmaceuticalsInnovation lab

Benchmark Upgrades Codexis, Inc (CDXS) to Buy, New Enzyme Coming Into Its Own

Benchmark Upgrades Codexis, Inc (CDXS) to Buy, New Enzyme Coming Into Its Own
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Robert wassermanCodexis inc